IP Library Granted Patent US 8,883,217
Granted Patent B2
US 8,883,217 · App. 14/155,410 · Granted Nov 11, 2014

Modified release formulations containing drug-ion exchange resin complexes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,217
App. No.
14/155,410
Granted
Nov 11, 2014
Kind
B2
Abstract

An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.

Claims (24)

1. A solid pharmaceutical orally disintegrating tablet composition comprising

(a) drug-ion exchange resin complex particles that are uncoated and which comprise amphetamine and dextroamphetamine bound to an ion exchange resin, and

(b) modified release coated drug-ion exchange resin complex particles which comprise amphetamine and dextroamphetamine bound to an ion exchange resin, wherein said modified release coated drug-ion exchange resin complex particles (b) further comprise a hydrophilic polymer or water insoluble polymer or copolymer in a matrix with the drug-ion exchange resin complex, wherein the modified release coating is over the drug-ion exchange resin complex-matrix, and

wherein the weight ratio of (a) to (b) is about 2:1 to about 1:10.

2. The composition according to claim 1 , wherein the modified release coating on the coated drug-ion exchange resin complex particles is a delayed release coating.

3. The composition according to claim 1 , wherein said modified release coated drug-ion exchange resin complex particles (b) further comprise a water insoluble polymer or copolymer in a matrix with the drug-ion exchange resin complex, wherein the modified release coating is over the drug-ion exchange resin complex-matrix.

4. The composition according to claim 3 , wherein the water insoluble polymer or copolymer is selected from the group consisting of a polyvinyl acetate polymer, cellulose acetate, acrylic based polymers or copolymers, cellulose phthalate, and mixtures thereof

5. The composition according to claim 1 , wherein the ion exchange resin in (a) and/or (b) is a strong acidic cation exchange resin.

6. The composition according to claim 5 , wherein said strong acidic cation exchange resin is a sulfonated copolymer of a polystyrene crosslinked with divinylbenzyl.

7. The composition according to claim 1 , wherein the drug-ion exchange resin complex particles of (a) and/or (b) have a particle size in the range of about 40 to about 250 microns.

8. The composition according to claim 1 , wherein said amphetamine and dextroamphetamine in (a) are bound to the same cation exchange resin.

9. The composition according to claim 8 , wherein said amphetamine and dextroamphetamine in (b) are bound to the same cation exchange resin.

10. An aqueous pharmaceutical liquid composition comprising:

(a) drug-ion exchange resin complex particles that are uncoated and which comprise amphetamine and dextroamphetamine bound to an ion exchange resin, and

(b) modified release coated drug-ion exchange resin complex particles which comprise amphetamine and dextroamphetamine bound to an ion exchange resin, wherein said modified release coated drug-ion exchange resin complex particles (b) further comprise a hydrophilic polymer or water insoluble polymer or copolymer in a matrix with the drug-ion exchange resin complex, wherein the modified release coating is over the drug-ion exchange resin complex-matrix, and

wherein the weight ratio of (a) to (b) is about 2:1 to about 1:10.

11. The composition according to claim 10 , wherein the modified release coating on the coated drug-ion exchange resin complex particles is a delayed release coating.

12. The composition according to claim 10 , wherein said modified release coated drug-ion exchange resin complex particles (b) further comprise a water insoluble polymer or copolymer in a matrix with the drug-ion exchange resin complex, wherein the modified release coating is over the drug-ion exchange resin complex-matrix.

13. The composition according to claim 12 , wherein the water insoluble polymer or copolymer is selected from the group consisting of a polyvinyl acetate polymer, cellulose acetate, acrylic based polymers or copolymers, cellulose phthalate, and mixtures thereof.

14. The composition according to claim 10 , wherein the ion exchange resin is a strong acidic cation exchange resin.

15. The composition according to claim 14 , wherein said strong acidic cation exchange resin is a sulfonated copolymer of a polystyrene crosslinked with divinylbenzyl.

16. The composition according to claim 10 , wherein the drug-ion exchange resin complex particles of (a) and/or (b) have a particle size in the range of about 40 to about 250 microns.

17. The composition according to claim 10 , wherein said amphetamine and dextroamphetamine of (a) are bound to the same cation exchange resin.

18. The composition according to claim 17 , wherein said amphetamine and dextroamphetamine of (b) are bound to the same cation exchange resin.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Sep 26, 2024
From: DEERFIELD MANAGEMENT COMPANY, L.P.
To: TRIS PHARMA, INC.; NEXTWAVE PHARMACEUTICALS INCORPORATED
Reel/Frame 069054/0362 →
SECURITY INTEREST Recorded Sep 26, 2024
From: TRIS PHARMA, INC.; PARK THERAPEUTICS, INC.
To: PROVIDENT BANK
Reel/Frame 069065/0576 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS Recorded Sep 25, 2018
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: TRIS PHARMA, INC.
Reel/Frame 047150/0169 →
GRANT OF SECURITY INTEREST IN PATENT RIGHTS Recorded Sep 24, 2018
From: TRIS PHARMA, INC.
To: DEERFIELD MANAGEMENT COMPANY, L.P., AS THE AGENT
Reel/Frame 047140/0290 →
PATENT SECURITY AGREEMENT Recorded Sep 5, 2017
From: TRIS PHARMA, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 043761/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2014
From: MEHTA, KETAN; TU, YU-HSING
To: TRIS PHARMA, INC
Reel/Frame 031976/0447 →